Arepanrix (pandemic influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted))
Conditional
- Region
- 🇪🇺 EU
- Active substance
- pandemic influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted)
- Company
- GlaxoSmithKline Biologicals S.A.
- Status
- Withdrawn
- Therapeutic area
- Influenza, Human; Immunization; Disease Outbreaks
- EU approval
- Tue 23 Mar 2010
- Designations
- Conditional
- Application
- EMEA/H/C/001201
- ATC
- J07BB02
- Official record
- www.ema.europa.eu
Indication
Prophylaxis of influenza in an officially declared pandemic situation. Pandemic influenza vaccine should be used in accordance with official guidance
Regulatory milestones
No milestones recorded in the last year.
Follow Arepanrix
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.